Literature DB >> 11169009

Phosphate removal and hemodialysis conditions.

R Pohlmeier1, J Vienken.   

Abstract

Hyperphosphatemia is frequently found in hemodialysis patients, and the association with an increased risk of mortality has been demonstrated. Other authors have linked hyperphosphatemia to increased cardiovascular mortality. The normalization of phosphate plasma levels is therefore an important goal in the treatment of end-stage renal disease patients. Absorption of phosphate from the food exceeds the elimination through a hemodialysis treatment, and this leads to a chronic phosphate load for the majority of hemodialysis patients. This imbalance should be improved by either a reduction of phosphate absorption or an increased removal of phosphate. A reduction of phosphate absorption can be achieved by reducing the amount of phosphate in the diet or by the administration of phosphate binders. Unfortunately, these measures imply practical difficulties, for example, a lack of patient compliance or other side effects. When considering modifications of the hemodialysis treatment, an essential understanding of the kinetics of dialytic phosphate removal is mandatory. Phosphate is unevenly distributed in different compartments of the body. Only a very small amount of phosphate is present in the easily accessible plasma compartment. The major part of phosphate removed during hemodialysis originates from the cytoplasm of cells. A transfer from intracellular space to the plasma and further from the plasma to the dialysate is necessary. However, if we consider improvement to phosphate removal by dialysis procedures, full dialyzer clearance is effective in only the initial phase of the dialysis treatment. After this initial phase, the transfer rate for phosphate from the intracellular space to the plasma becomes the rate-limiting step for phosphate transport. Attempts to improve this transfer rate have recently been investigated by acidosis correction, but turned out not to be consistently successful. Furthermore, modifications of the treatment schedule have been described in the literature as measures to influence the phosphate balance consistently. Successful improvements of the phosphate balance can be achieved specifically through increasing the frequency of the dialysis treatments.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11169009     DOI: 10.1046/j.1523-1755.2001.59780190.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  9 in total

1.  A wearable artificial kidney for patients with end-stage renal disease.

Authors:  Victor Gura; Matthew B Rivara; Scott Bieber; Raj Munshi; Nancy Colobong Smith; Lori Linke; John Kundzins; Masoud Beizai; Carlos Ezon; Larry Kessler; Jonathan Himmelfarb
Journal:  JCI Insight       Date:  2016-06-02

2.  Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.

Authors:  Christopher W McIntyre; Pearl Pai; Graham Warwick; Martin Wilkie; Alex J Toft; Alastair J Hutchison
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 8.237

3.  Association of circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function.

Authors:  Mengjing Wang; Li You; Haiming Li; Yong Lin; Zhijie Zhang; Chuanming Hao; Jing Chen
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-18       Impact factor: 8.237

4.  Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate.

Authors:  Veerle P Persy; Geert J Behets; Marc E De Broe; Patrick C D'Haese
Journal:  Int J Nephrol Renovasc Dis       Date:  2009-04-01

5.  Haemocompatibility and ion exchange capability of nanocellulose polypyrrole membranes intended for blood purification.

Authors:  Natalia Ferraz; Daniel O Carlsson; Jaan Hong; Rolf Larsson; Bengt Fellström; Leif Nyholm; Maria Strømme; Albert Mihranyan
Journal:  J R Soc Interface       Date:  2012-02-01       Impact factor: 4.118

6.  Treatable Leukoencephalopathy in a Patient with Hypophosphatemia.

Authors:  Masahiro Okazaki; Makito Hirano; Tomoki Iwatsu; Masaki Yamana; Hidekazu Suzuki; Takao Satou; Susumu Kusunoki
Journal:  Case Rep Neurol       Date:  2017-01-03

7.  Application of dynamic optimisation for planning a haemodialysis process.

Authors:  Wojciech Stecz; Radoslaw Pytlak; Aleksandra Rymarz; Stanislaw Niemczyk
Journal:  BMC Nephrol       Date:  2019-07-02       Impact factor: 2.388

8.  Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials.

Authors:  Yan Zhu; Jinlan Rao; Xueling Liao; Jihong Ou; Wei Li; Chao Xue
Journal:  Int Urol Nephrol       Date:  2021-03-06       Impact factor: 2.370

9.  Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.

Authors:  Jinmei Yin; Jun Yin; Rongli Lian; Peiqiu Li; Jing Zheng
Journal:  BMC Nephrol       Date:  2021-07-01       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.